Sevelamer suspension in children with end-stage renal disease

International Journal of Pharmaceutical Compounding

Volumn 11, Issue 1, 2007, Pages 20-24

  McElhiney, Linda F ^a  

^a INDIANA UNIVERSITY HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNAGEL; ALUMINUM CARBONATE; ALUMINUM HYDROXIDE; ALUMINUM HYDROXYCARBONATE; ALUMINUM PHOSPHATE; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM PHOSPHATE; CITRATE CALCIUM; LANTHANUM CARBONATE; MAGNESIUM DERIVATIVE; MAGNESIUM HYDROXIDE; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER; TUMS; UNCLASSIFIED DRUG;

ALUMINUM OVERLOAD; BLOOD VESSEL CALCIFICATION; CALCIFICATION; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG LABELING; DRUG PACKAGING; DRUG STABILITY; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPERPHOSPHATEMIA; KIDNEY FAILURE; PHOSPHATE BLOOD LEVEL; REVIEW; SOFT TISSUE CALCIFICATION; UNSPECIFIED SIDE EFFECT;

EID: 33847274131     PISSN: 10924221     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. St. Peter WL, Lewis, MJ. Chronic renal insufficiency and end-stage renal disease. Pharmacotherapy: A Pathophysiologic Approach. 4th ed. New York, NY: McGraw-Hill; 2000: 919-930.
2. Huybrechts KF, Caro JJ, Wilson DA et al. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis. Value in Health 2005; 8(5): 549-561.
3. Ribeiro S, Ramos A, Brandao A et al. Cardiac valve calcification in hemodialysis patients: Role of calcium-phosphate metabolism. Nephrol Dial Transplant 1998; 13(8): 2037-2040.
4. Levin NW, Hulbert-Shearon TE, Strawderman RL et al. Which causes of death are related to hyperphosphatemia in hemodialysis (HD) patients? J Am Soc Nephrol 1998; 9: 217A.
5. [No author listed.] Wolters Kluwer Health. Facts and Comparisons. [Wolters Kluwer Health Website.] Available at: www.factsandcomparisons.com. Accessed August 23, 2006.
6. [No author listed.] MICROMEDEX Healthcare Series Online. [Thomson Micromedex Website.] Available at: www.thomsonhc.com. Accessed February 13, 2006.
7. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342(20): 1478-1483.
8. Salusky IB, Goodman WG. Adynamic renal osteodystrophy: Is there a problem? J Am Soc Nephrol 2001; 12(9): 1978-1985.
9. Mahdavi H, Kuizon BD, Gales B et al. Sevelamer hydrochloride: An effective phosphate binder in dialyzed children. Pediatr Nephrol 2003; 18(12): 1260-1264.
10. [No author listed.] Lexi-Comp, Inc. [Lexi-Comp Online Website.] Available at: http://online.lexi.com/cronline. Accessed August 28, 2006.
11. Oh J, Wunsch R, Turzer M et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 2002; 106(1): 100-105.
12. United States Pharmacopeial Convention, Inc. USP Pharmacists' Pharmacopeia. Rockville, MD: US Pharmacopeial Convention, Inc.; 2005: 408-413.